From September 1973 to October 1974, 34 patients with small cell carcinoma of the lung were treated with monthly courses of BCVP: BCNU 60 mg/M2 i.v., cyclophosphamide 800 mg/M2 i.v., and vincristine 1.5 mg/M2 i.v. on day 1 and procarbazine 100 mgm/M2 p.o./day from day 1-10. Six patients had limited disease and 28 had extensive disease. Twenty four patients had prior radiotherapy to the primary tumor. The objective response rate to BCVP in evaluable patients with measurable disease was 18/31 (58%) with 3 complete (CR) and 15 partial responses (PR). The response to BCVP in patients who had received no prior radiotherapy was 7/10 with 3 CR. Leukopenia was the major toxicity. WBC count was less than 1500 in 11 cases. Mean WCB nadir was 2200. There were no drug related deaths. Mean duration of response is +108 days (53 to 218 days). 6/18 responders remain in remission. Patients with limited disease have a mean survival of +196 days from start of BCVP; those with extensive disease have a mean survival of +132 days. The responders and nonresponders have similar mean survivals (+138 and +131 days) but 9/18 responders are alive while only 1/13 nonresponders survives. This combination of cytotoxic drugs has a significant objective response rate in small cell carcinoma of the lung and merits further evaluation in the overall management of this neoplasm.
|Original language||English (US)|
|Journal||Proceedings of the American Association for Cancer Research|
|State||Published - Jan 1 1975|
ASJC Scopus subject areas